This document is a publication of a new patent application (US20260085286A1) filed with the USPTO. The application, assigned to Kenichiro Hasumi, describes an "Anti-tumor immune response enhancer" which utilizes a composition of phospholipids, referred to as "cPLs adjuvant," to maintain and enhance the anti-tumor activity of TADC in the tumor microenvironment. The inventors claim that this composition can suppress tumor growth and induce cytokine production by maturing dendritic cells.

As this is a patent application, it does not impose direct regulatory obligations or compliance deadlines on entities. However, it represents new intellectual property in the field of cancer therapeutics and immunotherapy. Companies involved in drug development, particularly in oncology and immunology, should be aware of this filing as it may impact future research, development, and patent landscapes in this area.